See: Araris Biotech at Bio-Europe | Popgen Tech

Araris Biotech AG is a Swiss-headquartered company pioneering the development of its novel antibody-drug conjugate (ADC) coupling technology to enable efficient and precise production of ADCs.

Its switching platform enables any drug payload to be attached to ‘off the shelf’ antibodies, without the need for pre-antibodies.

The resulting ADCs showed very high activity at low doses and an improved therapeutic index compared to several FDA-approved ADCs. Araris is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich.

In October, the company closed a $24 million funding round, bringing the total funds raised to date to $40 million.

The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors including Wille AG and the Institute for Follicular Lymphoma Innovation. The round also included participation from existing investors VI Partners, Schroders Capital, btov Partners and Redalpine. Damir Illich, Ph.D. van Wille AG and Sophie Allauzen, Ph.D. from the Institute for Follicular Lymphoma Innovation will also join the Araris team as board observers.

Proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the company’s proprietary linker technology, as Araris moves closer to clinical development.

At Bio-Europe we spoke to Philipp Spycher, CEO of Araris Biotech.